Drugs › Gonadotropin releasing hormone receptor agonist
Generic name
Leuprolide: adverse event reports filed with FDA
663 reports list it as a suspect or interacting product, 2005–2026. Class: Gonadotropin releasing hormone receptor agonist. Also reported as Leuprolide /00726901/.
- 663
- reports as suspect product
- 0% of all reports · about 31 a year
- 106
- reports, 12 months to June 2026
- 79 in the 12 months before
- 79%
- marked serious by the reporter
- 50.5% across the class
- 7.2%
- record death among outcomes, as reported
- 48 reports · not verified by FDA
663 adverse event reports received by FDA list leuprolide, a generic name as a suspect or interacting product, from February 2005 to June 2026. A further 953 reports list it only as a concomitant medication, and those are not counted in the figures on this page.
In the 12 months to June 2026, 106 reports listed it, up 34% from 79 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 31 reports a year and 0% of the 20,646,523 reports in the database, and 1.1% of the reports for the gonadotropin releasing hormone receptor agonist class. How many people take it is not in the data, so a count is not a rate of occurrence.
Reporters most often recorded drug ineffective (11.3%), product storage error (6.6%) and off label use (5.4%). A report can list several reactions, so shares add to more than 100%; 219 different terms appear across these reports. Drug ineffective is recorded in 11.3% of these reports, a larger share than in the median gonadotropin releasing hormone receptor agonist drug (5.8%).
79% of the reports are marked serious by the reporter (50.5% across the class); 7.2% record death among the outcomes and 30.9% record hospitalisation, as reported. 38.5% of the reports came from other health professionals, and the largest patient age group is 65 to 74 (18.7%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Leuprolide reports recording the termmedian drug in gonadotropin releasing hormone receptor agonist
- Drug ineffectivethe medicine did not work as expected11.3%75
- Product storage errorthe product was stored wrongly6.6%44
- Off label useused for a purpose or in a way not on the label5.4%36
- Disease progressionthe disease advanced5.3%35
- Treatment failurethe treatment did not work5%33
- Fatiguetiredness3.5%23
- Product use in unapproved indicationused for a purpose not on the label3.5%23
- Drug dependencedependence on a medicine2.6%17
- Product quality issuea problem with the product itself2.4%16
- Respiratory depressionslow or shallow breathing2.4%16
- Intentional product misusedeliberate use not as intended2.3%15
- Victim of child abuse2.3%15
- Painpain, site not specified2.1%14
- Pulmonary embolisma blood clot in the lung2.1%14
- Drug abusemisuse of a medicine2%13
- Ovarian hyperstimulation syndrome2%13
- Hot flusha hot flush1.8%12
- Product use issuea problem in how the product was used1.8%12
- Epidural lipomatosis1.7%11
- Juvenile idiopathic arthritis1.7%11
- Obesity1.7%11
- Child abuse1.4%9
- Headachehead pain1.4%9
- Hereditary optic atrophy1.4%9
- Dyspnoeashortness of breath1.2%8
- Febrile neutropeniafever with low white blood cells1.2%8
- Inappropriate schedule of product administrationthe product was taken at the wrong times1.2%8
- Pituitary apoplexy1.2%8
Top 30 of 219 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 7 drugs in the gonadotropin releasing hormone receptor agonist class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 61,409 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 67.9% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Prostate cancer | 131 | 19.8% |
| Prostate cancer metastatic | 42 | 6.3% |
| Hormone-refractory prostate cancer | 23 | 3.5% |
| Breast cancer | 20 | 3% |
| Ovulation induction | 8 | 1.2% |
| Breast cancer metastatic | 7 | 1.1% |
The indication field is filled in by the reporter and is often blank; shares are of all 663 reports.
Drugs most often listed in the same reports
| Drug (any role in the report) | Reports | Share of Leuprolide reports |
|---|---|---|
| Enzalutamide | 62 | 9.4% |
| Letrozole | 60 | 9% |
| Bicalutamide | 54 | 8.1% |
| Docetaxel | 52 | 7.8% |
| Abiraterone | 49 | 7.4% |
| Prednisone | 40 | 6% |
| Lorazepam | 23 | 3.5% |
| Pantoprazole | 23 | 3.5% |
| Cabazitaxel | 19 | 2.9% |
| Celecoxib | 19 | 2.9% |
Other products listed in reports where Leuprolide is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.
In context
| Measure | Leuprolide | Gonadotropin releasing hormone receptor agonist | All reports |
|---|---|---|---|
| Reports as suspect product | 663 | 61,409 | 20,646,523 |
| Share of that pool | — | 1.1% | 0% |
| Reports, latest 12 months | 106 | — | 1,332,454 |
| Marked serious | 79% | 50.5% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 72 | 177 | 91 |
| Hospitalisation recorded, per 1,000 reports | 309 | 151 | 213 |
| Consumer-filed share | 15.2% | 47.9% | 45.8% |
| Top term, share of reports | Drug ineffective 11.3% | median 5.8% | 6.3% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Other drugs in the gonadotropin releasing hormone receptor agonist class
| Drug | Name type | Reports | Latest 12 months | Marked serious |
|---|---|---|---|---|
| Eligard | brand | 44,385 | 2,388 | 38.1% |
| Zoladex | brand | 7,058 | 396 | 88.5% |
| Leuprolide acetate | generic | 4,951 | 702 | 90.1% |
| Goserelin | generic | 2,789 | 383 | 95.9% |
| Supprelin | brand | 815 | 12 | 18% |
| Fensolvi | brand | 748 | 114 | 4.4% |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.
Questions about Leuprolide reports
How many adverse event reports has FDA received for Leuprolide?
663 reports list Leuprolide as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 106 of them arrived in the latest 12 months. Another 953 list it only as a concomitant medication.
What reactions are recorded in Leuprolide reports?
drug ineffective (11.3%), product storage error (6.6%), off label use (5.4%), disease progression (5.3%) and treatment failure (5%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Leuprolide was responsible.
How serious are the reports?
79% are marked serious by the reporter. Among the outcomes recorded, 7.2% of reports include death and 30.9% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
other health professional (38.5%), physician (30.3%) and consumer or non-health professional (15.2%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Leuprolide rising?
106 reports in the 12 months to June 2026, up 34% from 79 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Leuprolide was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Leuprolide?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Leuprolide as a suspect or interacting product; reports listing it only as a concomitant medication (953) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.